Search clinical trials for: Iloprost inhalation

Total 1839 results

University of Oklahoma

Completed

Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD) (Iloprost)

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension

United States
Yonsei University

Unknown

Effects of Iloprost on Pulmonary Oxygenation in Obese Patients During One-lung Ventilation

Pulmonary Infection | Lung Cancer (Including Metastatic Cancer)
Interstitial Lung Disease Study Group, Korea

Unknown

Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis

Pulmonary Fibrosis | Pulmonary Hypertension

Korea, Republic of
Actelion

Completed

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis | Pulmonary Hypertension

United States
Actelion

Withdrawn

Safety and Efficacy of Inhaled Iloprost in Pediatric Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Bayer

Completed

Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)

Pulmonary Arterial Hypertension

Germany, Austria
National Cancer Institute (NCI)

Completed

Iloprost in Preventing Lung Cancer in Former Smokers

Lung Carcinoma

United States
Gachon University Gil Medical Center
Bayer; Seoul National University Hospital; Seoul National University Bundang... and other collaborators

Completed

Effect of BMPR-2 Gene Mutations on Hemodynamic Response by Iloprost Inhalation in Pulmonary Arterial Hypertension (PILGRIM)

Pulmonary Arterial Hypertension

Korea, Republic of
National Cancer Institute (NCI)

Not yet recruiting

Oral Iloprost for the Prevention of Lung Cancer In Former Smokers

Chronic Obstructive Pulmonary Disease | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Tobacco-Related Carcinoma | Bronchial Epithelial Dysplasia

United States
Charite University, Berlin, Germany
Schering-Plough

Terminated

Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis (ILODOSE)

Systemic Sclerosis

Germany
Actelion

Terminated

The "Power 15 Study": Safety Study of Inhalation of Ventavis With the Power Disc-15 Setting

Pulmonary Hypertension

United States
Actelion

Terminated

Iloprost Power Disc-15 in Pulmonary Arterial Hypertension (INHALE-15)

Pulmonary Arterial Hypertension

United States
Loma Linda University

Withdrawn

Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction at Altitude

Hypoxic Pulmonary Vasoconstriction

United States
National Center for Research Resources (NCRR)
University of Pittsburgh

Completed

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis

Systemic Sclerosis | Raynaud Disease
Lund University Hospital
Bayer

Withdrawn

Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost

Respiratory Distress Syndrome | Persistent Pulmonary Hypertension

Sweden
University of Colorado, Denver
National Cancer Institute (NCI)

Completed

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

Lung Cancer | Precancerous Condition

United States
Bayer

Completed

Observation of Patients With Primary Pulmonary Hypertension Receiving Prescribed Ventavis Inhalation Therapy Regarding Safety and Efficacy for up to 4 Years

Hypertension, Pulmonary

Italy, Spain, France, Germany, Portugal, United Kingdom
University of Chicago

Terminated

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

Pulmonary Hypertension

Israel, United States
Bayer

Completed

Hypertension Study of Ventavis® Inhalation Therapy in the Treatment of Patients With Pulmonary Arterial Hypertension (VENIS)

Pulmonary Hypertension

Korea, Republic of
Bayer

Completed

Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension

Hypertension, Pulmonary

Belgium, France, Spain, Netherlands, Italy, Portugal, Poland
Bayer

Completed

Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients (DAILY)

Pulmonary Arterial Hypertension

France
Bayer

Completed

Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension

Hypertension, Pulmonary
Bayer

Completed

Inhaled Iloprost in the Treatment of Patients With Pulmonary Hypertension up to 4 Years (OPTION)

Pulmonary Hypertension

Turkey
Bayer

Completed

Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension (IVENT)

Hypertension, Pulmonary

Russian Federation
VA Loma Linda Health Care System
Actelion

Unknown

Effects of Iloprost on Hypoxic Pulmonary Vasoconstriction and Exercise Capacity at High Altitude

Hypoxic Pulmonary Vasoconstriction

United States
Bayer

Completed

Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study (IBUKI)

Hypertension, Pulmonary

Japan
Bayer

Completed

Efficacy of Ventavis Used in Real-life Setting. (SPHERA)

Pulmonary Arterial Hypertension

Poland
Actelion

Completed

Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension (PROWESS 15 Ext)

Pulmonary Arterial Hypertension

United States, Germany, Austria
Bayer

Completed

Iloprost Therapy in Patients With Critical Limb Ischemia

Peripheral Arterial Disease

Hungary
Actelion

Terminated

Ventavis® Registry Protocol (RESPIRE)

Pulmonary Arterial Hypertension

United States
Seoul St. Mary's Hospital
The Catholic University of Korea

Completed

The Effect of Iloprost on Oxygenation During One-lung Ventilation for Lung Surgery

Lung Cancer

Korea, Republic of
Bayer

Completed

Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation (COMPHI)

Pulmonary Hypertension

Portugal
Bayer

Completed

Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension (VENTASTEP)

Hypertension, Pulmonary

Germany
Heidelberg University

Completed

Iloprost-Study: Comparison of Nitric Oxide to Iloprost (Ventavis) for Treatment of Pulmonary Hypertension in Children After Cardiopulmonary Bypass Surgery

Pulmonary Hypertension

Germany
Carmel Medical Center

Unknown

Inhaled Iloprost for Disproportionate Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease (COPD) (COPDVEN)

Chronic Obstructive Pulmonary Disease

Israel
Hannover Medical School

Terminated

Combination Therapy of Bosentan and Aerosolized Iloprost in Idiopathic Pulmonary Arterial Hypertension (IPAH)

Hypertension

Germany
Bayer

Completed

Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

Hypertension, Pulmonary

Japan
Actelion

Completed

Iloprost Power 15 in Pulmonary Arterial Hypertension (PROWESS 15)

Pulmonary Arterial Hypertension

United States, Austria, Germany
Bayer
Dra. Pilar Escribano Subías - Coordinator - HU 12 de Octubre - Madrid (Spain)

Completed

Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System (Inventa)

Pulmonary Arterial Hypertension

Spain
Yonsei University

Completed

Effect of Iloprost on Pulmonary Oxygenation in Patients With Low Diffusing Capacity During One-lung Ventilation

Lung Cancer

Korea, Republic of
Amsterdam UMC, location VUmc

Completed

The Effect of Iloprost on Capillary Recruitment and Insulin Sensitivity in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Insulin Sensitivity/Resistance

Netherlands
Shanghai Jiao Tong University School of Medicine

Completed

Study of Inhaled Iloprost in Pediatric Pulmonary Hypertension (PH) After Surgery

Pulmonary Hypertension

China
Actelion

Completed

Trial of Iloprost Inhaled Solution as Add-On Therapy With Bosentan in Subjects With Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension | Pulmonary Hypertension | Ayerza Syndrome

United States
Bayer

Completed

Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)

Primary Hypertension

China
Eicos Sciences, Inc.

Completed

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Raynaud Phenomenon Secondary to Systemic Sclerosis

United States
Heidelberg University
Bayer

Withdrawn

Iloprost for Bridging to Heart Transplantation in PH (BRIDGE)

Pulmonary Hypertension | Chronic Left Ventricular Failure

Germany
Yonsei University

Completed

Effects of Iloprost on Pulmonary Hemodynamics and Oxygenation in Patients of Chronic Obstructive Pulmonary Disease During One-lung Ventilation

Chronic Obstructive Pulmonary Disease | Video-assisted Thoracoscopic Surgery

Korea, Republic of
Shanghai Jiao Tong University School of Medicine
Cardiothoracic Surgical Group of Chinese Society of Pediatric Surgery

Completed

Multicenter Study of Iloprost Inhaled in Pulmonary Hypertension After Repair of Congenital Heart Diseases (CHD)

Pulmonary Hypertension

China
Jakob Stensballe, MD, PhD
Innovation Fund Denmark; Independent Research Fund Denmark

Completed

Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in Patients With Septic Shock Suffering From Organ Failure (COMBAT-SHINE)

Septic Shock

Denmark
Bayer

Completed

Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20) (VENTASWITCH)

Hypertension, Pulmonary

Germany

3

Subscribe